A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment.

Trial Profile

A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Fesoterodine (Primary) ; Oxybutynin
  • Indications Mild cognitive impairment; Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 27 Apr 2016 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
    • 27 Apr 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top